Ambrx Biopharma Inc.

Ambrx Biopharma — Investor Day (February 2023)

19 slides from Ambrx Biopharma's investor day presentation, Feb 24, 2023

  1. Slide 1: Analyst and Investor Day February 24, 2023

    Slide 1: Analyst and Investor Day February 24, 2023

    Analyst and Investor Day February 24, 2023 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, are "forward-looking" statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such

  3. Slide 3: ARX788 Anti-HER2 ADC for Patients with Post-Enhertu HER2+ Metastatic Breast Cancer

    Slide 3: ARX788 Anti-HER2 ADC for Patients with Post-Enhertu HER2+ Metastatic Breast Cancer

    ARX788 Anti-HER2 ADC for Patients with Post-Enhertu HER2+ Metastatic Breast

  4. Slide 4: Efficacy Signal Seen in Post-Enhertu Patients with ARX788

    Slide 4: Efficacy Signal Seen in Post-Enhertu Patients with ARX788

    Efficacy Signal Seen in Post-Enhertu Patients with ARX788 In October 2022, Ambrx strategically reprioritized its pipeline and paused further internal development of ARX-788, while seeking partnership ACE-Breast-03 study - Clinical study evaluating ARX788 in metastatic HER+ breast cancer (mBC) post-E

  5. Slide 5: Enhertu changed the breast cancer ADC landscape, but many patients progress

    Slide 5: Enhertu changed the breast cancer ADC landscape, but many patients progress

    Enhertu changed the breast cancer ADC landscape, but 24.2% of patients on Enhertu progress within 12 months No post-Enhertu data supporting the effectiveness of Kadycla and/or Tukysa potentially creates a new large market opportunity with no standard of care

  6. Slide 6: Post-Enhertu Market Could be a Billion Dollar Opportunity

    Slide 6: Post-Enhertu Market Could be a Billion Dollar Opportunity

    Post-Enhertu Market Could be a Billion Dollar Opportunity Estimated Drug treated patients in 3L+ (ie, 3L or later) HER2+ BC: 10,000 to > 14,000, depending on source 9,800 drug-treated patients per DRG, March 2020 report; estimate for 2028, 7MM >14,000 patients per HER2 competitors Roche and AstraZen

  7. Slide 7: Rationale for Continuing Evaluation of ARX788 in post-Enhertu mBC Patients

    Slide 7: Rationale for Continuing Evaluation of ARX788 in post-Enhertu mBC Patients

    Rationale for Continuing Evaluation of ARX788 in post-Enhertu mBC Patients Preliminary data from paused studies provide rationale for anti-tumor activity in post-Enhertu and post Kadcyla, as well as HER2 low patients Completed study (ACE-Breast-01) demonstrates robust response rate in the HER2 metas

  8. Slide 8: Planned Phase 2 Study of Patients Post-Enhertu

    Slide 8: Planned Phase 2 Study of Patients Post-Enhertu

    Planned Phase 2 Study of Approximately 30 Patients Post-Enhertu Amend existing ACE-Breast-03 protocol and submit to FDA (approx. 3-month process) Leverage existing / open clinical trial sites in ACE-Breast-03 to enable quicker study start Patients with no more than 3 prior lines of therapy and recen

  9. Slide 9: ARX517 Anti-PSMA ADC for Prostate and Other Cancers

    Slide 9: ARX517 Anti-PSMA ADC for Prostate and Other Cancers

    ARX517 Anti-PSMA ADC for Prostate and Other Cancers

  10. Slide 10: ARX517 - APEX-01 Phase 1 Trial Design

    Slide 10: ARX517 - APEX-01 Phase 1 Trial Design

    ARX517 - APEX-01 Phase 1 Trial Design Dose Expansion in metastatic-castration resistant prostate cancer (mCRPC) (Up to 40 Subjects) MTD or RP2D Expansion 0.32 mg/kg C1 0.64 mg/kg C2 1.07 mg/kg C3 1.4 mg/kg C4 1.7 mg/kg C5 2.0 mg/kg C6 2.4 mg/kg C7 Objectives Primary Safety Tolerability MTD RP2D Seco

  11. Slide 11: The Case for ARX517 in mCRPC

    Slide 11: The Case for ARX517 in mCRPC

    The Case for ARX517 in mCRPC PSMA is highly expressed (89%) in metastatic castration resistant prostate cancer (mCRPC), as well as neovasculature of various solid tumors PSMA is a clinically validated target and an established market for mCRPC Pluvicto has validated the PMSA as an effective prostate

  12. Slide 12: Appendix

    Slide 12: Appendix

    Appendix

  13. Slide 13: ARX788 – A Novel Anti-HER2 Antibody–Drug Conjugate (ADC)

    Slide 13: ARX788 – A Novel Anti-HER2 Antibody–Drug Conjugate (ADC)

    ARX788 – A Novel Anti-HER2 Antibody–Drug Conjugate (ADC) Binding domain Site specific conjugation Light Chain Heavy Chain ARX788 ARX788 is novel ADC comprised of an anti-HER2 mAb and a potent tubulin inhibitor payload AS269 that is site-specifically conjugated to the antibody via a synthetic amino a

  14. Slide 14: ACE-Breast-01 results with ARX788

    Slide 14: ACE-Breast-01 results with ARX788

    ACE-Breast-01 69 patients were enrolled in China, ORR was 65.5%, the DCR was 100% and the median progression-free survival was 17.02 months. ARX788 was well tolerated with most adverse events being grade 1 or 2 and were manageable, low systemic toxicity was observed, no DLT or drug-related deaths oc

  15. Slide 15: Summary of ARX788 Safety Data (All Cohorts)

    Slide 15: Summary of ARX788 Safety Data (All Cohorts)

    ARX788 (All Treated Population) Number of patients (%) ACE-Breast-01 (N=69) ACE-Pan-Tumor-01 (N=67) ACE-Gastric-01 (N=30) All AEs (regardless of causality) 69 (100%)​ 61 (91.0%) 29 (96.7%) Drug-related AEs (any grade) 67 (97.1%) 48 (71.6%) 28 (93.3%) All AEs ≥ Grade 3 and Grade 4 AEs 16 (23.2%) 23 (

  16. Slide 16: Key Takeaways: ACE-Breast-03 post T-DM1

    Slide 16: Key Takeaways: ACE-Breast-03 post T-DM1

    Key Takeaways ARX788 provided clinical benefit to patients previously treated with T-DM1 who had disease progression 4/7 patients also previously received HER2 TKI treatment Confirmed objective response rate (ORR) was 57.1% (4/7 pts) and an unconfirmed ORR of 71.4% (5/7 pts) Disease control rate (DC

  17. Slide 17: ARX788 Has Competitive Activity in the HER2 ADC Landscape

    Slide 17: ARX788 Has Competitive Activity in the HER2 ADC Landscape

    Data from ACE-Breast-01 Demonstrates that ARX788 Has Competitive Activity in the HER2 ADC Landscape FOR ILLUSTRAVE PURPOSES ONLY – Not a head-to-head analysis *ACE-Breast-01 conducted in China by Ambrx’s partner, NovoCodex Biologics **SeaGen acquired rights for RC48 for $200M as well as $2.4B in mil

  18. Slide 18: ARX788 Potential Mechanisms to Overcome Enhertu Resistance

    Slide 18: ARX788 Potential Mechanisms to Overcome Enhertu Resistance

    ARX788 Potential Mechanisms to Overcome Enhertu Resistance Cytotoxicity of ARX788 has a different MOA than Kadcyla (DM1) or Enhertu (DXd) ARX788 potentially maximizes the delivery and efficiency of the cytotoxic payload (AS269) into HER2-expressing tumor cells ARX788 potentially overcomes payload re

  19. Slide 19: ARX517 is the only ADC targeting PSMA in prostate cancer

    Slide 19: ARX517 is the only ADC targeting PSMA in prostate cancer

    ARX517 is the only ADC targeting PSMA in prostate cancer Binding domain Site specific conjugation Light Chain Heavy Chain ARX517 Potential to Become First-in-Class & Best-in-Class PSMA-ADC Fully humanized anti-PSMA monoclonal antibody (mAb) produced in CHO cells with site-specific incorporation of a

Source: SEC EDGAR · 8-K filed Feb 24, 2023

More decks from Ambrx Biopharma Inc.